We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.4B
1-Year Est. Return
163.13%
This Fund
S&P 500
This Quarter
Est. Return
+30.69%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.46B
AUM Growth
+$453M
(+9%)
Cap. Flow
-$312M
Cap. Flow
% of AUM
-5.72%
Top 10 Holdings %
Top 10 Hldgs %
38.94%
Holding
132
New
22
Increased
22
Reduced
29
Closed
18
Avg Time Held Equity + Options
10.3
quarters
Top 10 Avg Time Held Equity + Options
3.6
quarters
Top 20 Avg Time Held Equity + Options
5.2
quarters
Avg Time Held Equity only
10.4
quarters
Top 10 Avg Time Held Equity only
3.6
quarters
Top 20 Avg Time Held Equity only
5.2
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ArriVent BioPharma
AVBP
|
+$61.1M |
| 2 |
Cytokinetics
CYTK
|
+$52.8M |
| 3 |
Esperion Therapeutics
ESPR
|
+$33.3M |
| 4 |
Merck
MRK
|
+$32.2M |
| 5 |
Q32 Bio
QTTB
|
+$31M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RayzeBio, Inc. Common Stock
RYZB
|
+$147M |
| 2 |
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
|
+$93.5M |
| 3 |
United Therapeutics
UTHR
|
+$84.9M |
| 4 |
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
|
+$71.7M |
| 5 |
SpringWorks Therapeutics
SWTX
|
+$69.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.1% |
| 2 | Miscellaneous | 0.9% |
| 3 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
SVA
1
DELISTED
Sinovac Biotech, Ltd
SVA
| $340M | 6.23% |
2,718,735
| – | – |
2022 Q2
7 quarters
|
|
2
Eli Lilly
LLY
$1.08T
| $281M | 5.14% |
360,800
-4,600
| -1% | -$3.27M |
2023 Q1
4 quarters
|
|
3
Edgewise Therapeutics
EWTX
$4.02B
| $274M | 5.02% |
15,021,721
+454,545
| +3% | +$7.22M |
2021 Q1
12 quarters
|
|
4
Boston Scientific
BSX
$61.5B
| $224M | 4.11% |
3,273,000
-33,800
| -1% | -$2.17M |
2014 Q1
40 quarters
|
|
5
Intuitive Surgical
ISRG
$147B
| $197M | 3.6% |
493,100
-5,900
| -1% | -$2.23M |
2013 Q4
41 quarters
|
|
6
Biogen
BIIB
$33.8B
| $194M | 3.56% |
900,900
+73,300
| +9% | +$17.2M |
2013 Q2
43 quarters
|
|
|
7
Merck
MRK
$364B
| $174M | 3.18% |
1,316,000
+261,000
| +25% | +$32.2M |
2023 Q3
2 quarters
|
|
8
Janux Therapeutics
JANX
$1.04B
| $161M | 2.95% |
4,275,553
+957,626
| +29% | +$20.9M |
2021 Q2
11 quarters
|
|
9
Enliven Therapeutics
ELVN
$2.87B
| $158M | 2.9% |
8,998,338
| – | – |
2020 Q1
16 quarters
|
|
10
Tenet Healthcare
THC
$22B
| $123M | 2.26% |
1,173,300
-51,100
| -4% | -$4.59M |
2021 Q3
10 quarters
|
|
11
BioMarin Pharmaceuticals
BMRN
$10.6B
| $112M | 2.05% |
1,278,500
-292,910
| -19% | -$26.2M |
2021 Q3
10 quarters
|
|
12
DELISTED
Alpine Immune Sciences Inc
ALPN
| $106M | 1.95% |
2,680,496
+145,251
| +6% | +$4.29M |
2017 Q3
26 quarters
|
|
13
Disc Medicine
IRON
$2.15B
| $106M | 1.94% |
1,702,237
| – | – |
2021 Q1
12 quarters
|
|
14
Stryker
SYK
$108B
| $96.3M | 1.76% |
269,000
| – | – |
2020 Q3
14 quarters
|
|
15
ARS Pharmaceuticals
SPRY
$391M
| $94.4M | 1.73% |
9,240,887
| – | – |
2020 Q4
13 quarters
|
|
16
Sarepta Therapeutics
SRPT
$1.74B
| $90.3M | 1.65% |
697,500
| – | – |
2017 Q4
25 quarters
|
|
17
Ionis Pharmaceuticals
IONS
$7.06B
| $87.3M | 1.6% |
2,013,033
-51,764
| -3% | -$2.47M |
2022 Q2
7 quarters
|
|
18
Elevance Health
ELV
$91.9B
| $87.2M | 1.6% |
168,100
+26,600
| +19% | +$13.2M |
2023 Q4
1 quarter
|
|
19
Xtant Medical Holdings
XTNT
$44.9M
| $85.5M | 1.57% |
73,114,592
| – | – |
2013 Q2
43 quarters
|
|
20
Evolent Health
EVH
$523M
| $85.4M | 1.56% |
2,605,615
-140,917
| -5% | -$4.5M |
2021 Q3
10 quarters
|
|
|
21
DELISTED
SpringWorks Therapeutics
SWTX
| $84M | 1.54% |
1,707,331
-1,512,028
| -47% | -$69.9M |
2019 Q3
18 quarters
|
|
22
Keros Therapeutics
KROS
$217M
| $84M | 1.54% |
1,268,734
| – | – |
2020 Q2
15 quarters
|
|
23
Natera
NTRA
$57.2B
| $82.3M | 1.51% |
899,431
-55,050
| -6% | -$4.14M |
2015 Q3
34 quarters
|
|
24
Thermo Fisher Scientific
TMO
$249B
| $76.7M | 1.41% |
132,000
-11,800
| -8% | -$6.62M |
2013 Q2
43 quarters
|
|
25
DELISTED
Apellis Pharmaceuticals
APLS
| $76.3M | 1.4% |
1,297,800
+375,600
| +41% | +$23.9M |
2023 Q1
4 quarters
|
|
Similar funds
MYIA
SCM
BJL
BG
SNT
NL
RC
AC
OrbiMed's Q1 2024 Portfolio in Review
As of Q1 2024, OrbiMed held 132 positions worth $5.46B, up 9% from $5.01B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
OrbiMed withdrew a net $312M in Q1 2024, closing 18 positions and reducing 29 holdings. Its most notable exit was RayzeBio, Inc. Common Stock, an estimated $147M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Miscellaneous and Industrials.
Against the trend, OrbiMed opened a new position in ArriVent BioPharma worth $54.1M.
- OrbiMed's largest Q1 2024 buy was ArriVent BioPharma: 3,027,328 shares worth $54.1M.
- OrbiMed added most to Merck in Q1 2024, an estimated $32.2M increase.
- OrbiMed's biggest Q1 2024 reduction was SpringWorks Therapeutics, cutting an estimated $69.9M.
- OrbiMed fully exited RayzeBio, Inc. Common Stock in Q1 2024, selling an estimated $147M.
- OrbiMed's ten largest holdings make up 39% of its $5.46B portfolio in Q1 2024.
- OrbiMed opened 22 new positions and closed 18 in Q1 2024.
- OrbiMed's portfolio value rose 9% quarter-over-quarter to $5.46B.
Based on OrbiMed's 13F filing for Q1 2024, filed 15 May 2024.